• 1
    National Institutes of Health (NIH)/National Heart Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity: the evidence report. Washington, DC: U.S. Government Press, 1998.
  • 2
    Allison D, Fontaine K, Manson J, Stevens J, VanItallie T. Annual deaths attributable to obesity in the United States. JAMA. 1999; 282: 15301538.
  • 3
    Putnam S, Cerhan J, Parker A. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000; 10: 361369.
  • 4
    Schuurman A, Goldbohm R, Dorant E, van den Bradt P. Anthropometry in relation to prostate cancer risk in the Netherlands cohort study. Am J Epidemiol. 2000; 151: 541549.
  • 5
    Amling C, Kane C, Riffenburgh R. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001; 58: 723728.
  • 6
    Freedland S, Aronson W, Kane C, et al. Impact of obesity on biochemical control afer radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group. J Clin Oncol. 2004; 22: 446453.
  • 7
    Rohrmann S, Roberts W, Walsh P, Platz E. Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate. 2003; 55: 140146.
  • 8
    Kolonel L, Yoshizawa C, Hankin J. Diet and prostate cancer: a case-control study in Hawaii. Am J Epidemiol. 1988; 127: 9991012.
  • 9
    Ross R, Shimizu H, Paganini-Hill A, Honda G, Henderson B. Case-control studies of prostate cancer in blacks and whites in Southern California. J Natl Cancer Inst. 1987; 78: 869874.
  • 10
    Whittemore A, Kolonel L, Wu A, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995; 87: 652661.
  • 11
    Wolk A, Moantzoros C, Anderson S, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based case-control study. J Natl Cancer Inst. 1998; 90: 911915.
  • 12
    Yip I, Herber D, Aronson W. Nutrition and prostate cancer. Urol Clin North Am. 1999; 26: 403411.
  • 13
    Ku J, Kim M, Lee N, Park Y, Ahn J. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Adult Urol. 2003; 61: 132136.
  • 14
    World Health Organization. Physical status: the use and interpretation of anthropometry: a report of a WHO expert committee. Geneva: World Health Organization, 1995.
  • 15
    Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng/ml. N Engl J Med. 2004; 350: 22392246.
  • 16
    Riegman PH, Vlietstra RJ, Van der Korput JA, Brinkmann AO, Trapman J. The promoter of prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol. 1991; 5: 19211930.
  • 17
    Muller M, den Tonkelaar I, Thijssen J, Grobbee D, van der Schous Y. Endogenous sex hormones in men aged 40–80 years. Eur J Endocrinol. 2003; 149: 583589.
  • 18
    Amling C, Riffenburgh R, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004; 22: 439445.